Disclaimer: I am not a doctor and this is not medical advice.
Last year, I wrote about case studies of pathological BRCA1 and BRCA2 gene variants in trans people, and how clinicians take these mutations into account during transition treatment. While harmful BRCA mutations are best known for their effect of drastically increasing breast cancer and ovarian cancer risk in cisgender women, these variants represent a concern for transgender women as well, as transitioning with hormone therapy produces the growth of breast tissue considered histologically identical to that of cis women. Trans women can get breast cancer – UCSF Transgender Care has even published recommendations for when trans women should begin receiving regular mammograms – and having a harmful BRCA1/2 variant can increase their risk. (BRCA1/2 variants are also a concern for transgender men, who may still have breast tissue or ovaries, and even for cis men, who can face a higher risk of various cancers from these harmful variants as well.) Continue reading “Further publications on BRCA1/2 variants and their impact on transitioning”